Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

ROCKVILLE, Md., Feb. 16 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.  

Vanda reported a net loss of $9.2 million for the fourth quarter of 2009, compared to $7.7 million for the third quarter of 2009 and $7.5 million for the fourth quarter of 2008.  Total revenue for the fourth quarter of 2009 was $4.5 million, consisting of $2.6 million in upfront licensing revenue and $1.9 million in product revenue for inventory sold to Novartis Pharma AG (Novartis).  The remaining $197.4 million in deferred revenue relating to the $200.0 million upfront payment received from Novartis pursuant to the Fanapt™ (iloperidone) license agreement will be recognized ratably ($2.2 million per month) through May 2017.  Total expenses for the fourth quarter of 2009 were $13.8 million, compared to $7.7 million for the third quarter of 2009 and $7.7 million for the fourth quarter of 2008.  Research and development (R&D) expenses for the fourth quarter of 2009 were $2.3 million, compared to $2.1 million'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 Shimadzu Scientific ... amino acid analysis system developed jointly with Ajinomoto ... Station can analyze 38 amino acids in nine ... Station achieves high-speed analysis utilizing a fast application-specific ... provides accurate analytical results even under conditions with ...
(Date:7/23/2014)... StemGenex® , the leading resource ... aimed at improving the lives of patients dealing with ... Parkinson’s disease. StemGenex believes that a commitment to ... paramount when providing care to patients with degenerative diseases. ... therapy accessible to the millions of individuals currently living ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... 23, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic stem cell ... a multi-product healthcare company catering to the mother and child segment, ... patients across the PRC, Singapore , ... India , the Philippines and ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... TAIAN CITY, China, July 16 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, ... "Company"),one of the leading plasma-based pharmaceutical companies in the ... hosted a forum of,industry experts on July 10 - ... discuss future development strategies for the Company. , ...
... , , , ... announced today that it had closed its series A financing round. The infusion ... of technology that converts a wide variety of cellulosic materials (such as algae, ... , As part of the agreement, the lead investor ...
... , HALIFAX, July 15 /PRNewswire/ - Scientists in Atlantic Canada ... skin aging. Researchers were investigating the genetic cause of a ... causes skin on the hands, feet and face to be ... delays including effects on the brain. In the process, researchers ...
Cached Biology Technology:China Biologic Products Hosts its First Forum for Strategy and Development 2China Biologic Products Hosts its First Forum for Strategy and Development 3Canadian researchers discover gene related to the appearance of aging 2
(Date:7/23/2014)... by satellite over a 15-year period off the U.S. ... feed in specific locations each year, according to a ... PLOS ONE by Ladd Irvine from Oregon ... to mitigate human threats to the whale population. , ... recover since the establishment of protections in the mid-1960s. ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
(Date:7/23/2014)... , , , , , , , , ... , , , , , ... researchers are proposing that changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be ... , , , , , ... , , , , , ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... gets his new laser laboratory operational later this year, ... to pluck molecular bonds like a stringed musical instrument. ... of Chemistry, arrived at the University of Chicago in ... aid of ultrafast vibrational spectroscopy methods that he has ...
... maxillary sinuses. Those bulbous pouches on either side of the ... sinus infections than anything else. They were thought to be ... present value. Yet researchers led by the University of ... role in the shape and function of the human nose, ...
... March 12, 2013  Spiral Genetics, a cloud-based big data ... A financing, led by venture capital firm DFJ.  The ... create revolutionary tools that empower the bioinformatics community to ... company intends to use the funds to expand its ...
Cached Biology News:Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3The nose's unheralded neighbor 2The nose's unheralded neighbor 3Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 2Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 3
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: